Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report

Juliano Boufleur Farinha; Letícia Schwerz Weinert; Lidiane Pozza Costa; Marcelo Zanusso Costa; Patrícia Peres de Peres; Cláudia Fernandes Lorea

doi:10.1007/s13410-022-01076-1

Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report

Int J Diabetes Dev Ctries. 2022 Oct;42(4):787-790. doi: 10.1007/s13410-022-01076-1. Epub 2022 Apr 27.

Authors

Juliano Boufleur Farinha¹, Letícia Schwerz Weinert¹, Lidiane Pozza Costa¹, Marcelo Zanusso Costa¹, Patrícia Peres de Peres¹, Cláudia Fernandes Lorea¹

Affiliation

¹ Brazilian Company of Hospital Services, School Hospital at the Federal University of Pelotas, Dr Araújo Street 538, Pelotas, 96020360 Brazil.

Abstract

A patient with Prader-Willi syndrome (PWS), extreme obesity and hyperglycemia had her body weight increased considerably for 6 months, even with exercise and diet programs. Treatment with metformin and empagliflozin (12.5 mg/day) induced a weight loss of 14 kg (-10.3%) for 6 months and the reduction of glycated hemoglobin A_1c.

Keywords: Case report; Exercise; Obesity, Morbid; Prader-Willi syndrome; SGLT-2 inhibitors.

Publication types

Case Reports